Table 3.

Selected examples of epigenetic drugs under clinical evaluation in B-NHL patients as single agents.

Epigenetic drug class	Drug	Diseases	Sponsor	Trial identifier
HDAC inhibitor	Vorinostat	FL, indolent B-NHL, MCL	Merck Sharp & Dohme Corp.	NCT00875056
	Chidamide (Epidaza)	R/R B-NHL	Sun Yat-sen University	NCT03245905
	Abexinostat	R/R FL	Xynomic Pharmaceuticals, Inc.	NCT03934567
	Mocetinostat (MGCD0103)	DLBCL, FL	Memorial Sloan Kettering Cancer Center and MethylGene Inc.	NCT02282358
	Ricolinostat(ACY-1215)	R/R NHL	Acetylon Pharmaceuticals Inc. and Columbia University	NCT02091063
	Panobinostat	CLL	Peter MacCallum Cancer Centre, Australia	NCT01658241
	CDX101	Advanced lymphomas	Cancer Research UK and Oxford University Hospitals	NCT01977638
IDH1 inhibitor	Ivosidenib(AG-120)	Advanced hematologic malignancies with an IDH1 mutation	Agios Pharmaceuticals, Inc.	NCT02074839
BET bromodomaininhibitor	CPI-0610	Progressive lymphomas	Constellation Pharmaceuticals	NCT01949883
	BMS-986158	Lymphomas	Dana-Farber Cancer Institute	NCT03936465
	Molibresib (GSK525762)	NHL	GlaxoSmithKline	NCT01943851
EZH1/2 inhibitor	DS-3201b	R/R B-NHL	Daiichi Sankyo Co., Ltd.	NCT02732275
	CPI-1205	Progressive B-cell lymphomas	Constellation Pharmaceuticals	NCT02395601
	Tazemetostat	R/R B-NHL	Eisai Co., Ltd.	NCT03009344
	Tazemetostat	R/R NHL with EZH2 gene mutations	National Cancer Institute (NCI)	NCT03213665
PRMT inhibitor	JNJ-64619178	R/R B-NHL	Janssen Research & Development, LLC	NCT03573310
	GSK3326595	MDS, AML	GlaxoSmithKline	NCT03614728
	GSK3368715	DLBCL	GlaxoSmithKline	NCT03666988
DNMT inhibitor	Decitabine	R/R DLBCL	Mingzhi Zhang, Zhengzhou University	NCT03579082
EED inhibitor	MAK683	Advanced DLBCL	Novartis Pharmaceuticals	NCT02900651

EED, embryonic ectoderm development. Source: https://clinicaltrials.gov/.